共 50 条
- [31] A two-cohort, phase II, cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive, locally advanced, inflammatory, or early breast cancerCANCER RESEARCH, 2015, 75Swain, Sandra M.Ewer, Michael S.Douthwaite, HannahSzado, TaniaWaldron-Lynch, MaeveDang, Chau
- [32] Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLANCET ONCOLOGY, 2012, 13 (01): : 25 - 32Gianni, LucaPienkowski, TadeuszIm, Young-HyuckRoman, LasloTseng, Ling-MingLiu, Mei-ChingLluch, AnaStaroslawska, Elzbietade la Haba-Rodriguez, JuanIm, Seock-AhPedrini, Jose LuizPoirier, BrigitteMorandi, PaoloSemiglazov, VladimirSrimuninnimit, VichienBianchi, GiuliaSzado, TaniaRatnayake, JayanthaRoss, GrahamValagussa, Pinuccia
- [33] Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese settingJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (20) : 17933 - 17942Hu, ShanshanWu, YilaiLuan, JiajieWang, ShuowenFan, Guorong
- [34] 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trialLANCET ONCOLOGY, 2016, 17 (06): : 791 - 800Gianni, LucaPienkowski, TadeuszIm, Young-HyuckTseng, Ling-MingLiu, Mei-ChingLluch, AnaStaroslawska, Elzbietade la Haba-Rodriguez, JuanIm, Seock-AhPedrini, Jose LuizPoirier, BrigitteMorandi, PaoloSemiglazov, VladimirSrimuninnimit, VichienBianchi, Giulia ValeriaMagazzu, DomenicoMcNally, VirginiaDouthwaite, HannahRoss, GrahamValagussa, Pinuccia
- [35] COST-UTILITY ANALYSIS OF ADJUVANT PERTUZUMAB-BASED REGIMEN IN WOMEN WITH HER2-POSITIVE BREAST CANCER IN ITALYVALUE IN HEALTH, 2018, 21 : S45 - S45Pradelli, L.Zaniolo, O.Caputo, A.Roussel, M.Tournier, C.
- [36] Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumabMEDICINE, 2019, 98 (36)Wang, XinleCai, LijingYe, FengLi, MengqiMa, LiGeng, CuizhiSong, ZhenchuanLiu, Yueping
- [37] A pilot study of pertuzumab, trastuzumab and eribulin for patients with advanced HER2 positive breast cancerCANCER RESEARCH, 2016, 76Ishihara, M.Tamaru, S.Oda, H.Yamashita, Y.Tono, Y.Mizuno, T.Katayama, N.
- [38] SAFETY OF TRASTUZUMAB AND PERTUZUMAB FOR PATIENTS WITH PREVIOUSLY TREATED HER2 POSITIVE ADVANCED BREAST CANCERANNALS OF ONCOLOGY, 2014, 25Sakaguchi, HarunaIshihara, MikiyaSawaki, AkihikoNagaharu, KeikiOda, HiroyasuSugawara, YumikoTamaru, SatoshiYamashita, YoshikiMizuno, ToshiroKatayama, Naoyuki
- [39] Pertuzumab in neoadjuvant treatment of HER2-positive early breast cancerJOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (03): : 84 - 86Abraham, Jame
- [40] Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast CancerJOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (01) : 1 - 9Vieira, ClaudiaBorges, AndreiaPereira, Filipa F.Antunes, PedroRedondo, PatriciaAntunes, LuisLopes, Jose M.Goncalves, Francisco R.Borges, MarinaBento, Maria J.